Evaluating the Efficacy and Tolerability of ZED1227 in Subjects With Non-responsive Celiac Disease

NCT07298343 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

356

Enrollment

INDUSTRY

Sponsor class

Conditions

Celiac Disease

Interventions

DRUG: ZED1227 + SIGE
OTHER: Placebo

Sponsor

Dr. Falk Pharma GmbH

Collaborators

[object Object]